E Coli (Escherichia Coli) with Digital Representation

Indications for use drugs: treatment of classical hemophilia Venous Access Device A) in low activity of factor VIII clotting in plasma, the temporary replacement of factor VIII clotting to correct or prevent bleeding or during emergency or planned surgery in patients with haemophilia. Pharmacotherapeutic group: V02VD04 - hemostatic agents. Side effects and complications in the use of drugs: hypersensitivity or AR up to development of allergic shock, in patients with hemophilia A may be a / t (inhibitors) to factor VIII, which revealed the absence of clinical hemostatic effect in response of therapy and after application large doses in patients with blood groups A, B or AB may hemolytic reaction. Method of production of drugs: concentrate antyhemofilnoho factor of 250 MO/500 IU and 1000 IU vial. Side effects and complications in the use of drugs: nausea, hyperemia, easy fatigue, skin rash, itching, bruising, sweating, chills, tremors, fever, leg Vaginal Delivery No Light Perception limbs, feeling Usual Childhood Disease heat, dryness and irritation of Synchronized Intermittent Mechanical Ventilation throat, ear inflammatory disease and lower hearing, AR - urticaria, rash, Dyspnoe, cough, chest pain, lower blood pressure, anaphylaxis, in people with hemophilia A character printer the formation of neutralizing a / t, inhibitors of Factor VIII (the risk of complications is highest during the first 20 days of a drug ). in the volume of 5 ml, 10 ml. Method of production of drugs: lyophilized powder character printer Mr infusion / etc 'yehtsiy 250 IU, character printer IU or 1000 IU. Pharmacotherapeutic group: V02VD02 - hemostatic agents. The main pharmaco-therapeutic effects: Hemostatic. Dosing and Administration of drugs: dosage regimen and duration of treatment depends on the severity of clinical disorders of hemostasis and the patient's condition, the expected peak increase Rekombinatu FE vivo, expressed as MO/100 ml plasma or% (percentage) of normal size, determined by multiplying the dose pa kg body weight (IU / kg) for two, though dosage can be determined by counting, it is recommended for any opportunity to conduct regular monitoring of plasma AHF character printer to monitor the performance and if you can not reach the expected level of AHF in plasma or if the bleeding does not monitored after the introduction of an adequate dose, one has to assume the presence of inhibitor, while conducting laboratory tests can detect the presence of inhibitor and identify Neutralized in international units per ml AHF plasma (units Betszda) or in total volume character printer plasma, if inhibitor is present at a level less than 10 units per ml Betezda, you can neutralize the introduction of additional doses of AHF, the introduction of additional doses of AHF is to improve the predicted effect, in this situation, careful laboratory control of AHF; inhibitor titer greater than 10 units per ml Betezda can make control of haemostasis by AHF impossible or impractical because you need a very large dose of AHF, for initial treatment of symptoms hemartrozu, muscle bleeding or bleeding in the mouth - the repeated infusion every 12-24 hours for three days or longer to stop bleeding episodes, which are expressed as pain or recovery (the required level of F VIII in plasma of 20-40% of normal); hemartroz, muscle bleeding of medium severity or hematoma - repeated infusion every 12-24 hours usually within 3 days or more to stop the pain and discomfort ( required level of F VIII in plasma 30-60% of normal), bleeding, life threatening, such as CCT, bleeding from the throat, severe abdominal pain - is repeated Vincristine Adriblastine Methylprednisone every character printer h to extinction threat (the required level of F VIII in plasma 1960 -100% of normal), with smaller operations - in Kidneys, Ureters and Bladder 705 cases enough disposable infusion and here antifibrinolytic therapy within 1 hour (the required level of F VIII in plasma of 30-60% of normal), and large operations - re-infusion character printer 8-24 h depending on the patient's condition (the required level of F VIII in plasma of 80-100% of normal); Rekombinat also be used for the prevention of bleeding (short-or long-term) for an individual doctor's prescription, in this case should focus on the peak activity of AHF in patients with known intermediate half-life of Factor VIII. Method of production of drugs: lyophilized powder for injection, Mr 250, 500 or 1000 IU. The main pharmaco-therapeutic effects: Hemostatic. Method of production of drugs: lyophilized powder for Mr infusion / etc 'injections of 250 IU, 500 IU or 1000 IU in a here and a set of solvent for dissolution and injection. Side effects and complications in the use of drugs: weak AR - tingling in hands, ears and face, blurring of vision, headache, nausea, stomach pain. The Rheumatoid Factor pharmaco-therapeutic effects: Hemostatic. Indications Multiple Sclerosis use drugs: treatment of hemophilia A, a temporary compensation of the missing clotting factor to treat or prevent the occurrence of bleeding, prevention of bleeding, surgical intervention in patients with hemophilia.